AI Patient Pre-Screening
AI-powered automated chart review to accelerate patient enrollment and reduce site burden
Software · Cloud SaaSCompany source
Company profile
About Inato
Inato operates a global AI-powered platform that unites pharmaceutical sponsors, research sites, and patients to make clinical trials faster, more efficient, and more inclusive. The company addresses critical challenges in clinical research including site selection, patient recruitment, and trial diversity by leveraging artificial intelligence and real-time patient access data. Inato's platform serves over 6,000 research sites across 50+ countries and works with 25+ pharmaceutical sponsors to optimize trial planning, site selection, and patient enrollment. The company's core technology includes AI-powered site selection tools that match sponsors with qualified sites based on actual capabilities and patient access, and AI pre-screening capabilities that automate chart review to identify eligible patients and accelerate enrollment. By reducing site burden and streamlining workflows, Inato helps bring medical breakthroughs to underserved communities and diverse patient populations. The platform has demonstrated measurable impact, with case studies showing enrollment rates exceeding targets by up to 181%, 66% faster enrollment times, and significant improvements in patient diversity. Founded with a mission to create a world where all patients can access the right trials in their community, Inato is backed by global healthcare investors and co-develops its technology with forward-thinking pharmaceutical and site leaders.
Company description Inato official website
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Inato?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Asthma
- Atopic Dermatitis
- Cardiovascular Disease
- COPD
- Oncology
- Weight Loss/Obesity
Who it serves
- Clinical Research Organizations
- Pharma
- Research Sites
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: eClinPro Site CTMS, RealTime eClinical Solutions.
Geographic context
MarketsGlobal - 50+ countries · United States
Company sourceOfficial website
Company milestones
Platform expansion
Launched AI Site Selection capabilities (September 2025); Partnership with RealTime eClinical Solutions announced (September 2025); Integration with eClinPro Site CTMS (April 2026); Published validation study on multimodal LLM pipeline (November 2025); Won Fast Company's Most Innovative Companies award (2024); Fireside chat with Sanofi at SCOPEX discussing portfolio-level planning (June 2028 - likely typo for 2025)
Partnerships
Recorded partners
- eClinPro
- RealTime eClinical Solutions
- Sanofi
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
AI Site Selection
AI-powered site selection based on real-time patient access data and site capabilities
Software · Cloud SaaSCompany source
Inato Platform
AI-powered platform connecting sponsors, research sites, and patients for faster, more inclusive clinical trials
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Real-world validation of a multimodal LLM-powered pipeline for high-accuracy clinical trial patient matching.Communications medicine · Nov 22, 2025
Anticovid, a comprehensive open-access real-time platform of registered clinical studies for COVID-19.The Journal of antimicrobial chemotherapy · Sep 1, 2020
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
181% of enrollment target achieved
Phase II asthma trial
66% faster enrollment time
Oncology case study
85% diverse patient enrollment
Phase III COPD trial
115% of enrollment target achieved
Phase III CVD trial
123% of enrollment target achieved
Phase III atopic dermatitis trial
33% faster first patient screened (17 days sooner)
COPD study with AI pre-screening
90% reduction in chart review time
AI patient pre-screening
181 hours and $4,500 saved
Weight loss trial
85% Hispanic patient enrollment vs 16% goal
Asthma trial diversity
3x site interest
Multi-asset respiratory program
Sanofi
COPD trial using AI patient pre-screening to streamline screening and enrollment
Sites using AI screened first patient 33% faster (17 days sooner), 100% of sites actively enrolling, 80% of sites are high-performers
Anonymous Sponsor - Weight Loss Trial
Weight loss study using AI pre-screening to reduce site burden and accelerate enrollment
181 hours and $4,500 saved per site
Anonymous Sponsor - Asthma Trial
Phase II asthma trial to reach engaged community sites and improve patient diversity
181% of Inato's patient enrollment target achieved, 85% Hispanic patients enrolled vs 16% goal, 17 sites selected vs 10 planned
Anonymous Sponsor - Atopic Dermatitis Trial
Phase III atopic dermatitis trial
123% of Inato's patient enrollment target achieved
Anonymous Sponsor - COPD Trial
Phase III COPD trial focused on patient diversity
85% of patients enrolled were diverse
Anonymous Sponsor - CVD Trial
Phase III cardiovascular disease trial
115% of Inato's patient enrollment target achieved
Anonymous Sponsor - Oncology Trial
Oncology trial focused on accelerating enrollment
66% faster enrollment time
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Kourosh Davarpanah
Co-Founder & Chief Executive Officer
Liz Beatty
Co-Founder & Chief Strategy Officer
Jean-David Zeitoun
Co-Founder & Chief Medical Officer
Philippe Ravaud
Co-Founder & Chief Scientific Officer
Bastien Duret
Chief Technical Officer
Brad Cottreau
Chief Commercial Officer
Carly Cooperstein
Vice President of Trial Delivery
Remi Dupeuble
Vice President of Finance
06 · Company updates
Updates from Inato
Recent articles published on Inato's official website.
Inato Integrates With CRIO’s Site CTMS to Simplify Patient Screening
Read on Inato5 Takeaways From our Fireside Chat with Sanofi
Read on Inato181 Hours and $4,500 Saved: Inside One Weight Loss Trial With Inato
Read on InatoInato Integrates With eClinPro To Streamline Patient Screening and Enrollment
Read on InatoSCOPE Orlando 2026 Recap: How Data-Driven Sites Can Prove Patient Access to Win Trials and Accelerate Enrollment
Read on Inato07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.